Assignee
NEWAVE PHARMACEUTICAL INC
US·19 granted patents·26 pending applications·46 citations·filing 2017–2024
Top patents by PatentIndex Score
45 records- 0197US11365206B2BCL-2 inhibitorsNEWAVE PHARMACEUTICAL INC·Filed 2020·Granted Jun 21, 2022·7 cites·30 claims
- 0296US11993610B2BCL-2 inhibitorsNEWAVE PHARMACEUTICAL INC·Filed 2022·Granted May 28, 2024·3 cites·20 claims
- 0396US11680072B2Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseasesNEWAVE PHARMACEUTICAL INC·Filed 2022·Granted Jun 20, 2023·4 cites·3 claims
- 0496US11279711B2Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseasesNEWAVE PHARMACEUTICAL INC·Filed 2020·Granted Mar 22, 2022·6 cites·21 claims
- 0595US10377755B2BCL-2 inhibitorsNEWAVE PHARMACEUTICAL INC·Filed 2018·Granted Aug 13, 2019·11 cites·13 claims
- 0692US12410190B2Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseasesNEWAVE PHARMACEUTICAL INC·Filed 2023·Granted Sep 9, 2025·1 cites·12 claims
- 0792US10239872B2Therapeutic agents for the treatment of HBV infectionNEWAVE PHARMACEUTICAL INC·Filed 2018·Granted Mar 26, 2019·5 cites·3 claims
- 0889US11903950B2BCL-2 inhibitorsNEWAVE PHARMACEUTICAL INC·Filed 2019·Granted Feb 20, 2024·3 cites·28 claims
- 0987US2025179090A1Condensed heterocyclic derivatives as bcl-2 inhibitors for the treatment of neoplastic diseasesNEWAVE PHARMACEUTICAL INC·Filed 2024·Application pending·0 cites
- 1086US2024425520A1Bcl-2 inhibitorsNEWAVE PHARMACEUTICAL INC·Filed 2024·Application pending·0 cites
- 1184US12220419B2BCL-2 inhibitorsNEWAVE PHARMACEUTICAL INC·Filed 2019·Granted Feb 11, 2025·2 cites·30 claims
- 1283US11501284B2Substituted pyrazines as inhibitors of BTK, and mutants thereofNEWAVE PHARMACEUTICAL INC·Filed 2020·Granted Nov 15, 2022·1 cites·7 claims
- 1381US10501456B2Therapeutic agents for the treatment of HBV infectionNEWAVE PHARMACEUTICAL INC·Filed 2019·Granted Dec 10, 2019·1 cites·7 claims
- 1481US2025051329A1Bcl-2 inhibitorsNEWAVE PHARMACEUTICAL INC·Filed 2024·Application pending·0 cites
- 1580US10253029B2Dual-warhead covalent inhibitors of FGFR-4NEWAVE PHARMACEUTICAL INC·Filed 2017·Granted Apr 9, 2019·2 cites·19 claims
- 1680US2025045728A1Inhibitors of btk and mutants thereofNEWAVE PHARMACEUTICAL INC·Filed 2024·Application pending·0 cites
- 1778US2024180924A1Bcl-2 inhibitorsNEWAVE PHARMACEUTICAL INC·Filed 2023·Application pending·0 cites
- 1875US12086788B2Substituted pyrazines as inhibitors of BTK, and mutants thereofNEWAVE PHARMACEUTICAL INC·Filed 2022·Granted Sep 10, 2024·0 cites·23 claims
- 1970US2020297724A1Covalent inhibitors of cdk-7NEWAVE PHARMACEUTICAL INC·Filed 2019·Application pending·0 cites
- 2070US2021171523A1Bcl-2 inhibitorsNEWAVE PHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 2170US2025114374A1Bcl-2 inhibitorsNEWAVE PHARMACEUTICAL INC·Filed 2022·Application pending·0 cites
- 2269US10456397B2Covalent inhibitors of CDK-7NEWAVE PHARMACEUTICAL INC·Filed 2019·Granted Oct 29, 2019·0 cites·18 claims
- 2368US2020071329A1Bcl-2 inhibitorsNEWAVE PHARMACEUTICAL INC·Filed 2019·Application pending·0 cites
- 2467US2020223841A1Novel therapeutic agents for the treatment of hbv infectionNEWAVE PHARMACEUTICAL INC·Filed 2019·Application pending·0 cites
- 2567US2025099481A1Bcl-2 inhibitorsNEWAVE PHARMACEUTICAL INC·Filed 2022·Application pending·0 cites
- 2664US10195200B2Covalent inhibitors of CDK-7NEWAVE PHARMACEUTICAL INC·Filed 2017·Granted Feb 5, 2019·0 cites·18 claims
- 2764US2026014260A1Mdm2 degraderNEWAVE PHARMACEUTICAL INC·Filed 2023·Application pending·0 cites
- 2862US2025136620A1Btk degraderNEWAVE PHARMACEUTICAL INC·Filed 2023·Application pending·0 cites
- 2960US2024390368A1Inhibitor of btk and mutants thereofNEWAVE PHARMACEUTICAL INC·Filed 2022·Application pending·0 cites
- 3060US2025129047A1Isoquinoline derivatives as mutant egfr modulators and uses thereofNEWAVE PHARMACEUTICAL INC·Filed 2022·Application pending·0 cites
- 3159US2024217964A1Quinuclidinone analogues as anticancer agentsNEWAVE PHARMACEUTICAL INC·Filed 2022·Application pending·0 cites
- 3259US2025145639A1Mutant kras modulators and uses thereofNEWAVE PHARMACEUTICAL INC·Filed 2022·Application pending·0 cites
- 3358US2024058457A1Btk degraderNEWAVE PHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 3457US2024166646A11h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseasesNEWAVE PHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 3556US12569564B2Spirocyclic MDM2 modulator and uses thereofNEWAVE PHARMACEUTICAL INC·Filed 2022·Granted Mar 10, 2026·0 cites·7 claims
- 3656US2023346779A1Dosage form compositions comprising an inhibitor of btk and mutants thereofNEWAVE PHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 3756US2023382900A1Inhibitors of btkNEWAVE PHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 3854US2023295183A1Hot melt extruded solid dispersions containing a bcl2 inhibitorNEWAVE PHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 3953US12552784B21H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseasesNEWAVE PHARMACEUTICAL INC·Filed 2020·Granted Feb 17, 2026·0 cites·3 claims
- 4052US2023089530A1Quinuclidinone analogues as anticancer agentsNEWAVE PHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 4151US2022363689A1Inhibitor of btk and mutants thereofNEWAVE PHARMACEUTICAL INC·Filed 2020·Application pending·0 cites
- 4249US2022372042A1Condensed heterocycles as bcl-2 inhibitorsNEWAVE PHARMACEUTICAL INC·Filed 2020·Application pending·0 cites
- 4347US2022135569A1Inhibitor of btk and mutants thereofNEWAVE PHARMACEUTICAL INC·Filed 2020·Application pending·0 cites
- 4446US12583853B21H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseasesNEWAVE PHARMACEUTICAL INC·Filed 2019·Granted Mar 24, 2026·0 cites·6 claims
- 4545US11479555B2Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinaseNEWAVE PHARMACEUTICAL INC·Filed 2019·Granted Oct 25, 2022·0 cites·9 claims
Join the waitlist — get patent alerts
Get an alert when NEWAVE PHARMACEUTICAL INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →